Last checked at 3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News2
GSK Share
Chat7
GSK Share
Trades5,637
GSK
Live RNS2
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,598.00
Bid:
1,597.50
Ask:
1,598.50
Change:
-168.50 (-9.54%)
Spread:
1.00 (0.063%)
Open:
1,616.50
High:
1,620.00
Low:
1,589.50
Prev. Close:
1,766.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GlaxoSmithKline first-quarter sales up 11% but profit falls
Wed, 27th Apr 2016 12:02
(ShareCast News) - GlaxoSmithKline posted a rise in first-quarter sales and core earnings per share amid healthy demand for the company's new drugs.First-quarter sales were up 11% in sterling terms to £6.2bn, with core earnings per share 14% higher at 19.8p, beating analysts' forecasts of 17.9p.New product sales came in at £821m, up from £269m in the first quarter of 2015. This was driven by HIV, respiratory and meningitis vaccines.Glaxo said new pharmaceutical product sales now represent 20% of total pharmaceutical sales.The company said that within its Respiratory portfolio, the growth in sales of new products offset about 70% of the decline in Seretide/Advair.The company said on Wednesday that it expects 10% to 12% growth in 2016 core EPS at constant currency as it declared a 19p per share dividend for the first quarter. It continues to expect 80p for full year 2016 and 2017.Pre-tax profit for the quarter fell to £560m from £9.9bn in the first quarter of last year while net income slid to £282m from £8.1bn a year before, which was boosted by proceeds from the group's three-part transaction with Novartis.Chief executive officer Andrew Witty said: "This strong first quarter performance demonstrates the momentum we have across the group driven by growth in sales of our new products, effective cost control and execution of our restructuring and integration plans. We also continue to see good progression of novel assets in our core R&D therapy areas."Glaxo said its restructuring and integration programme delivered incremental cost savings of £0.4bn and it remains on course for £3bn annual cost savings by the end of next year.Atif Latif, director of trading at Guardian Stockbrokers, said: "EPS growth of 10-12% (core growth of 8%) is positive in a low rate environment where the ability of companies to at least maintain if not progressively grow dividends is a core objective." At 1400 BST, GSK shares were up 2.3% to 1,492.42p.
More News
3 Jan 2024 08:58
LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.
Read more3 Jan 2024 07:54
LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data
(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.
Read more29 Dec 2023 13:01
LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023
(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.
Read more20 Dec 2023 13:29
GSK buys rights to Hansoh Pharma antibody-drug conjugate
(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.
Read more19 Dec 2023 15:36
German court quashes CureVac patent after challenge by BioNTech
CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue
*Read more18 Dec 2023 17:21
Energy stocks lift UK's FTSE 100, Vodafone shines
Vodafone jumps as Iliad offers to merge Italian units
*Read more18 Dec 2023 10:07
GSK's dostarlimab trial in endometrial cancer meets primary endpoint
(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.
Read more18 Dec 2023 07:55
LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000
(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.
Read more18 Dec 2023 07:18
GSK sees success in Jemperli endometrial cancer trial
(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.
Read more17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more